Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
  • 0 views
  • 27 Jan, 2021
  • 29 locations
  • 0 views
  • 25 Oct, 2022
  • 26 locations
A Phase I/II, Single-Arm, Open Label Study to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With Neurofibromatosis Type 1 (NF1) Related Symptomatic, Inoperable Plexiform Neurofibromas (PN) (SPRINKLE) (SPRINKLE)

This study is designed to define a dosing regimen and assess the pharmacokinetics(PK) and safety of the granule formulation; the study will also include descriptive analyses of exploratory efficacy endpoints. The study will inform the benefit risk profile of the granule formulation in children aged ≥ 1 to < 7 …

  • 0 views
  • 13 Oct, 2022
  • 7 locations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

anti-cancer agents
cytokines
solid tumor
ensartinib
bone marrow infiltration
  • 1032 views
  • 25 Oct, 2022
  • 108 locations
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

This is a phase I, open-label, dose-escalation study to determine the MTD of selumetinib when combined with the standard dose of azacitidine. Treatment will begin within 28 days of screening

essential thrombocythemia
myelofibrosis
chronic myelomonocytic leukemia
polycythemia
ruxolitinib
  • 14 views
  • 25 May, 2022
  • 1 location
Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours (INSPECT)

Phase I and II study of the MEK inhibitor Selumetinib given twice daily on 5 out of 7 days in children with NF1 and inoperable plexiform neurofibromas or progressive/relapsed optic pathway

gilbert disease
ejection fraction
tumor resection
plexiform neurofibroma
neutrophil count
  • 49 views
  • 27 Feb, 2022
  • 1 location
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (SEL-TH-1601)

In this research study the researchers want to learn more about the effects (both good and bad) the study drug selumetinib has on participants with neurofibromatosis type II (NF2) related tumor

sargramostim
biologic agent
seizure
nitrosoureas
MRI
  • 639 views
  • 28 Apr, 2022
  • 1 location
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating

  • 0 views
  • 11 Oct, 2022
  • 37 locations
Phase I/II Trial Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC

This phase I/II trial studies the best dose of selumetinib and how well it works with durvalumab and tremelimumab in treating participants with stage IV non-small cell lung cancer or that has

durvalumab
monoclonal antibody therapy
recurrent disease
glomerular filtration rate
liver metastasis
  • 8 views
  • 25 Oct, 2022
  • 1 location
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

This phase 3 trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously

glomerular filtration rate
giant cell astrocytoma
hypertension
metastatic disease
vincristine
  • 17 views
  • 24 Oct, 2022
  • 66 locations